DCPH News and Press, Deciphera Pharmaceuticals Inc. From 05/15/20

Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...

Deciphera Pharmaceuticals Inc (DCPH) Q1 2020 Earnings Conference Call May 5, 2020 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commer...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc.   (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020 , 4:30 p.m. ET Operator Continue reading

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q1 GAAP EPS of -$1.36 misses by $0.05 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- NDA for Ripretinib for the Treatment of Advanced GIST Under Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Launch - - COVID-19 Business Update Provided; Clinical and Commercial Milestone Timing Affirmed - - First Qua...

Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free...

Broadwind Energy (NASDAQ: BWEN ) +60% . on $19M order . More news on: Broadwind Energy, Inc., TrovaGene, Inc., SmileDirectClub, Inc., Stocks on the move, , Read more ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) is up  16%  premarket on light volume on the heels on Blueprint Medicines' plunge after announcing unsuccessful results from late-stage study of avapritinib in gastrointestinal stromal tumor (GIST) patients. More news on: Deciphera...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020. In connection with the earnings re...

There are plenty of intriguing biotech stocks on the market right now, and many of them are trading at a steep discount due to the coronavirus pandemic. However, no matter how exciting a company's prospects might be, investors still need to do their due diligence before choosing to invest in any...